HK1199040A1 - Use of antibody - Google Patents

Use of antibody

Info

Publication number
HK1199040A1
HK1199040A1 HK14112443.2A HK14112443A HK1199040A1 HK 1199040 A1 HK1199040 A1 HK 1199040A1 HK 14112443 A HK14112443 A HK 14112443A HK 1199040 A1 HK1199040 A1 HK 1199040A1
Authority
HK
Hong Kong
Prior art keywords
antibody
Prior art date
Application number
HK14112443.2A
Other languages
English (en)
Chinese (zh)
Inventor
Fulvio Dacquisto
Mauro Perretti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of HK1199040A1 publication Critical patent/HK1199040A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK14112443.2A 2011-12-14 2014-12-10 Use of antibody HK1199040A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB201121564A GB201121564D0 (en) 2011-12-14 2011-12-14 Use of antibody
PCT/GB2012/000906 WO2013088111A1 (fr) 2011-12-14 2012-12-14 Utilisation d'anticorps

Publications (1)

Publication Number Publication Date
HK1199040A1 true HK1199040A1 (en) 2015-06-19

Family

ID=45560502

Family Applications (1)

Application Number Title Priority Date Filing Date
HK14112443.2A HK1199040A1 (en) 2011-12-14 2014-12-10 Use of antibody

Country Status (7)

Country Link
US (2) US10752677B2 (fr)
EP (1) EP2791167B1 (fr)
JP (1) JP6406642B2 (fr)
ES (1) ES2670999T3 (fr)
GB (1) GB201121564D0 (fr)
HK (1) HK1199040A1 (fr)
WO (1) WO2013088111A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201702091D0 (en) * 2017-02-08 2017-03-22 Medannex Ltd Specific binding molecules
GB201813137D0 (en) 2018-08-10 2018-09-26 Medannex Ltd Cancer treatment with an antibody
JP7224628B2 (ja) * 2019-02-01 2023-02-20 国立研究開発法人産業技術総合研究所 抗ｍｃ１６抗体
GB201904717D0 (en) * 2019-04-03 2019-05-15 Univ London Queen Mary Treatment and diagnosis of mental disorders
CA3238416A1 (fr) 2021-11-18 2023-05-25 Henry Charles Wilson HAYS Polytherapie pour le cancer

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8625941D0 (en) * 1986-10-30 1986-12-03 Sandoz Ltd Substituted alpha-amino acids
US5051364A (en) 1989-02-16 1991-09-24 The Salk Institute For Biological Studies Anti-lipocortin-I and anti-lipocortin-II monoclonal antibodies
US5565338A (en) 1990-06-04 1996-10-15 La Jolla Institute For Allergy And Immunology Suppressor T-cell hybridoma and production of allergen specific glycosylation inhibiting factor
US5462990A (en) * 1990-10-15 1995-10-31 Board Of Regents, The University Of Texas System Multifunctional organic polymers
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
WO2003057715A2 (fr) 2001-12-28 2003-07-17 The Regents Of The University Of California Nouveau ligand implique dans la transmigration leucocytaire a travers l'endothelium et ses utilisations
CN1726395A (zh) 2002-12-17 2006-01-25 北京诺赛基因组研究中心有限公司 胰腺癌的特异标记
US8198020B2 (en) 2003-08-22 2012-06-12 Potentia Pharmaceuticals, Inc. Compositions and methods for enhancing phagocytosis or phagocyte activity
EP1670510A1 (fr) 2003-09-24 2006-06-21 Peter Krammer Anticorps diriges contre les annexines, leur utilisation a des fins therapeutiques et diagnostiques, utilisation des annexines a des fins therapeutiques et diagnostiques
EP1755646A2 (fr) 2004-06-02 2007-02-28 Sidney Kimmel Cancer Center Cibles vasculaires permettant de detecter, d'imager et de traiter la neoplasie ou la croissance neovasculaire
US20090233906A1 (en) 2006-05-26 2009-09-17 Francis Fang Imidazoazepinone compounds
GB0822011D0 (en) 2008-12-02 2009-01-07 Queen Mary & Westfield College Treatment
CN103097414B (zh) 2010-06-09 2016-05-18 伦敦大学玛丽皇后和威斯特-弗尔德学院 膜联蛋白1抗体
US20130088110A1 (en) * 2011-10-07 2013-04-11 Michael Charles Bertsch SMT System
GB201121561D0 (en) * 2011-12-14 2012-01-25 Queen Mary & Westfield College Transgenic animal
US9209965B2 (en) 2014-01-14 2015-12-08 Microsemi Semiconductor Ulc Network interface with clock recovery module on line card
JP2016197324A (ja) * 2015-04-03 2016-11-24 キヤノン株式会社 情報処理装置、情報処理装置の制御方法、及びプログラム
GB201702091D0 (en) 2017-02-08 2017-03-22 Medannex Ltd Specific binding molecules

Also Published As

Publication number Publication date
EP2791167A1 (fr) 2014-10-22
ES2670999T3 (es) 2018-06-04
US20150004164A1 (en) 2015-01-01
EP2791167B1 (fr) 2018-02-14
GB201121564D0 (en) 2012-01-25
US10752677B2 (en) 2020-08-25
WO2013088111A1 (fr) 2013-06-20
US20210079076A1 (en) 2021-03-18
JP2015501829A (ja) 2015-01-19
JP6406642B2 (ja) 2018-10-17

Similar Documents

Publication Publication Date Title
HRP20180640T1 (hr) Anti-b7-h3 antitijelo
HK1255608A1 (zh) 抗htra1抗體及使用方法
IL259826A (en) Anti-alphabetatisiar antibody
GB201103955D0 (en) Antibodies
GB201112056D0 (en) Antibodies
IL229254A0 (en) Therapeutic antibodies
HK1201843A1 (en) Anti-polyubiquitin antibodies and methods of use
ZA201403760B (en) Anti-cd98 antibodies and methods of use thereof
HK1199842A1 (en) Anti-siglec-15 antibodies and uses thereof -15
TWI563004B (en) Anti-hxcr1 antibody
HK1200839A1 (en) Bispecific -cell activator antibody
HK1199040A1 (en) Use of antibody
EP2684869A4 (fr) Préparation de 3-mercaptopropionates
EP2714713A4 (fr) Purification d'anticorps
EP2769988A4 (fr) Anticorps anti-gap43
EP2714074A4 (fr) Anticorps anti-emr1
HUE041625T2 (hu) Terápiás ellenanyagok
GB201105866D0 (en) This is about me